Supplementary figure 2: miR-124 induction at week 8 vs. baseline in blood samples from RA patients who received placebo or ABX464 (50 or 100 mg) once daily.

*** p <0.001, ** p <0.01 versus placebo

The median values, represented by horizontal bars, were 0.2, 174.5 and 119.2 for placebo, ABX464 50 mg and 100 mg q.d., respectively. Interquartile ranges were 1.682, 19702 and 6257 for placebo, ABX464 50 mg and 100 mg q.d., respectively. Note that for 5 patients in the placebo group, levels of miR-124 were below the limit of detection.